Introduction
Adrenergic hyperactivity is one of the key pathophysiological features of heart failure, and adverse effects of beta1 adrenoceptor ( 1 AR) activation are well established as are the clinical benefits of 1 AR blockade. In contrast, the role of the 3 AR in human heart failure and its potential as a therapeutic target has not been examined. A recent position paper from the European Society of Cardiology on novel therapies for heart failure highlighted the therapeutic potential and mechanisms of action of 3 AR agonist treatment.
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Myocardial 3 AR expression is increased in heart failure 2 and, unlike the 1/ 2 ARs, the 3 AR does not desensitize to agonist activation. 3 The 3 AR mediates a negative inotropic effect in normal myocardium 4, 5 and this might become increasingly important with up-regulation of the receptor in heart failure. While perhaps protective in early stages, myocardial depression with 3 AR activation has been proposed to be deleterious as heart failure progresses. 4, 6 Based on these initial findings, it was suggested 3 AR antagonists should be useful in heart failure and that 3 AR agonists, when used for other purposes, are harmful. 7 An increase in 3 AR-mediated Ca 2+ channel inhibition in the failing heart 8 is expected to be harmful. However, Na + export by stimulation of the cardiac myocyte Na + -K + pump that the 3 receptor also mediates 9 is potentially beneficial because the intracellular Na + concentration ([Na
in cardiac myocytes is raised in heart failure, 10 and the high [Na + i ] has adverse effects on contraction, 10 energy metabolism, and myocardial oxidative stress. 11 As reviewed, 12 raised [Na + i ] appears to be a treatment target because treatments with proven efficacy in human trials stimulate Na + i export by stimulating the Na + -K + pump in myocytes. Conversely, treatments proven to be harmful inhibit the pump. 12 The potential usefulness of 3 AR agonists is indicated by a differential haemodynamic effect of a 3 AR agonist given intravenously to sheep before and after stable severe heart failure had been induced. As expected for effects of 3 AR activation on contractility in the normal heart, 5 the drug given before heart failure had been induced had a negative inotropic effect. In contrast, it improved contractile performance of the failing heart. 9 Here we examine changes in LVEF after 6-month treatment with the 3 AR agonist mirabegron in patients with heart failure and reduced LVEF, and examine safety of such treatment. Treatment also had to include a beta-blocker and, if tolerated, ACE inhibitors and aldosterone antagonists. Mirabegron is currently approved for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
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Methods
An expanded version of the Methods section is available in the Supplementary material online. mirabegron vs. placebo in patients with chronic heart failure, conducted at the tertiary referral centre, The Heart Centre at Rigshospitalet, University of Copenhagen, Denmark. We screened adult patients (≥18 years) with a clinical diagnosis of heart failure for inclusion from 1 November 2013 until 25 March 2015. Patients with ischaemic or non-ischaemic stable heart failure with a preliminary LVEF <40% determined by echocardiography were eligible for inclusion if they were in NYHA class II or III on optimized evidence-based pharmacotherapy, unaltered for >4 weeks. Patients also had to be in sinus rhythm to ensure optimal imaging. Treatment had to include a beta-blocker to reduce or prevent potential non-specific stimulation of 1 ARs by the study drug.
Study design and patients
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Exclusion criteria were unstable cardiac conditions, acute myocardial infarction or revascularization within 3 months, initiation of CRT within 6 months, significant valve obstruction, heart failure due to uncorrected thyroid disease, myocarditis, or pericardial constriction, uncontrolled hypotension (symptomatic systolic blood pressure <90 mmHg) or hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg), hepatic or renal insufficiency, pregnancy, treatment with tricyclic antidepressant or CYP2D6 substrates other than beta-blockers, or treatment with digoxin. Patients expected not to be compliant with the protocol were also excluded.
Randomization
For random, double-blind allocation of patients in a 1:1 ratio to mirabegron or placebo, each sample of study drug was first randomly assigned a study number at the pharmacy by a computer-based system in blocks of six, i.e. three numbers were allocated to mirabegron and three were allocated to placebo with random variation within each block.
Study drug dosages
The recommended dose of mirabegron for overactive bladder is 25-50 mg o.d. and the reported highest daily dose given for >5 T 1/2 (steady-state level) is 300 mg, 13 which we chose as the target. Treatment with mirabegron or matching placebo was started at the lowest dose of 25 mg b.i.d. and, if tolerated, increased after 1 week to 50 mg b.i.d., after 2 weeks to 100 mg b.i.d., and after 3 weeks to the target of 150 mg b.i.d. The maximum tolerated dose (MTD) was defined as the dose that did not increase heart rate by >25 b.p.m. above baseline or above 90 b.p.m., cause symptomatic hypotension, increase systolic blood pressure >25 mmHg above the baseline or above 150 mmHg, cause arrhythmia, other clinically significant cardiovascular adverse events, or other significant adverse events or symptoms. If a dose was not tolerated, it was reduced to a lower one that had been tolerated. If the MTD or 150 mg b.i.d. mirabegron or matching placebo was well tolerated after 1 week 300 mg was given as a single dose once daily for the remaining period. All usual medications were continued as prescribed. Compliance was defined as adherence to the study drug by ≥90% as assessed by pill count at the end of the study.
For safety, patients were monitored in the outpatient clinic by measurements of blood pressure and heart rate hourly for the first 4 h after the initial dose and after an increase in dose. If no significant adverse effects developed, they were followed in the outpatient clinic. After up-titration of the first 30 patients, no significant changes of blood pressure or heart rate were identified and observation time after each change in dose was reduced to 1 h.
Follow-up
Vital signs were assessed at follow-up in weeks 1, 2, 3, 5, 7, 14, and 26 to detect adverse effects of treatment. Blood was sampled for standard biochemical analysis (haemoglobin, white blood cell and platelet counts, renal and hepatic function, electrolytes, and glucose).
Endpoints
The primary endpoint was change in LVEF and, while use of echocardiography to screen for patients with reduced LVEF reflects clinical practice, we used the change in LVEF determined by cardiac computed tomography (CT) 14 as the endpoint to reduce variance and improve statistical power. LVEF was measured by CT angiography after patients were entered into the study before starting treatment and again after 6 months. We also determined changes in functional class, 6-min walking distance, maximum oxygen uptake (VO 2 max), NT-proBNP levels, cardiac output/stroke volume, left ventricular end-systolic (LVESV) and end-diastolic (LVEDV) volumes, left atrial (LA) volume, QT interval duration, and changes in numbers of premature supraventricular complexes (PSVCs) and premature ventricular complexes (PVCs), but the study was not powered to detect changes in these indices.
The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee for the Capital Region Copenhagen (H-3-2013-016) and monitored externally by the University of Copenhagen Good Clinical Practice Unit. All patients gave written informed consent.
Statistical methods
For sample size calculations, a difference of 4% (absolute number) in LVEF between the placebo and intervention group was considered clinically significant. With a power of 90%, a two-sided alpha-level of 5%, and an estimated standard deviation (SD) of change in LVEF of 4% by CT, the sample size was 46 (23 in each group). Assuming a drop-out of 30%, a total of 70 patients had to be included.
Statistical analysis was performed using SPSS. Normally distributed data are presented as mean ± SD and non-normally distributed data as median [interquartile range (IQR)]. Normally distributed within-individual changes from baseline to follow-up were evaluated using the paired t-test. For non-normally distributed continuous variables we used a non-parametric rank sum test. Interaction between baseline LVEF and change in LVEF was assessed by linear regression. Estimated between-group differences are presented with 95% confidence intervals (CIs). Comparison of categorical variables was made with 2 test or Fisher's exact test. A two-sided P-value of <0.05 was considered statistically significant. All analyses were performed on data from the modified intention-to-treat population, i.e. for all patients with data available at 6-month follow-up.
Results
Baseline characteristics
After screening of 142 patients, 70 (58 ± 12 years, 11% female) were included ( Figure 1 ). Of these, 35 were assigned to placebo treatment and 35 to treatment with mirabegron ( Table 1) . Heart failure was due to ischaemic heart disease in 31 patients (44%) and non-ischaemic disease in 39 (56%). Most (67, 96%) were in NYHA class II and only three were in class III. patients (56%) had a history of previous cardiac arrest, ventricular tachycardia (VT), or appropriate shocks from an implanted cardiac defibrillator (ICD). The mean LVEF was 33 ± 8% as assessed by echocardiography and 39 ± 10% as assessed by CT. We have previously reported LVEF measured by CT to be ∼5% points higher than LVEF measured by echocardiography.
14 There was a trend to patients randomized to treatment with mirabegron being older than patients treated with placebo (P = 0.05). Other baseline demographic and clinical characteristics were balanced between the treatment groups ( Table 1) .
Clinical characteristics at follow-up
At follow-up after 6 months, 61 patients (87%) had completed the study according to protocol (Figure 1 ). Thirty-four (97%) randomized to placebo treatment and 32 (91%) to treatment with mirabegron reached the target dose of 300 mg daily (P = 0.30). All patients completing the study were compliant, with pill counts >98% of dispensed pills. Two-thirds remained in the same NYHA class at follow-up ( Table 2 ). In total 12 patients had improved by one NYHA class at follow-up, 7 who were treated with placebo and 5 treated with mirabegron. Three patients given placebo but none treated with mirabegron had worsening dyspnoea. There was no difference in changes of blood pressure or heart rate between mirabegron-and placebo-treated patients ( Table 2) . No changes in renal, hepatic, or thyroid function and no changes in blood glucose, haemoglobin, white blood cells, platelets, or electrolytes were seen (data not shown).
Left ventricular ejection fraction and volumes
For the primary endpoint-LVEF-the mean difference at 6 months was 0.4% (95% CI −3.5 to 3.8%) ( Figure 2A ). Neither treatment group had significant changes in LVEF, LVEDV, or LVESV from baseline to follow-up ( Table 2 ) and none of the parameters differed significantly between groups. The mean difference for LVEDV was 1 mL (−15 to 16 mL) and for LVESV −4 ml (−19 to 11 mL; Table 2 ).
Secondary outcomes
There were no significant changes in LA volume from baseline to follow-up within treatment groups, and changes in LA volume did not differ significantly between groups (−5 to 12 mL) ( Table 2) . No significant changes in stroke volume, cardiac output, QT interval, or numbers of PSVCs or PVCs were seen from baseline to follow-up within groups, and there were no differences in changes between groups. Mean NT-proBNP levels were only modestly elevated beyond the normal level at baseline, with large variance of levels. These results are consistent with the stable clinical state on optimized treatment required for entry into the study. There was no significant change in mean levels during treatment in either group ( 
Exploratory analysis
We explored results with a separate analysis of outcome for patients with baseline LVEF <40% vs. LVEF ≥40 % as assessed by CT. This analysis was based on the mechanistic rationale that benefit of a 3 AR agonist-induced Na + -K + pump-mediated decrease in cardiac myocyte [Na + i ] is expected to depend on the severity of heart failure. The analysis was not pre-specified.
In the groups of patients with LVEF <40% there was an increase in LVEF from baseline to follow-up for patients treated with mirabegron (mean difference 5.9%, 0.4-11.4%, P = 0.025, n = 8) ( Figure 2B ), whereas there was no significant change in the placebo group (mean difference 0.4%, −2.2 to 2.9%, P = 0.88, n = 17) ( Figure 2B ). The increases in LVEF were significantly different between mirabegron-and placebo-treated groups (mean difference 5.5%, 0.6-10.4%, P < 0.03) ( Figure 2B ). There was no significant change in LVEF for groups of patients with a baseline LVEF ≥40% who were treated with mirabegron or given placebo, and there were no between-group differences ( Figure 2C ). The patients in this subgroup had more dilated left ventricles as compared with the entire cohort, and the increase in stroke volume in the mirabegron-treated patients was associated with a reduction in systolic and unaltered diastolic volumes ( Table 3) .
For patients with an LVEF ≥40%, changes in LVEF, LVEDV, or LVESV from baseline to follow-up were similar within groups and there were no differences in changes between groups (data not shown). 
Safety and adverse events
Treatment was generally well tolerated. There were no changes in blood pressure or heart rate in the immediate observation period during initiation or up-titration of study drug or at 6-month follow-up ( Table 4) . Any adverse event was registered in 13 (37%) patients given placebo and in 20 (57%) given mirabegron (P = 0.09). Adverse effects were generally mild and transient, and only two patients dropped out due to side effects.
Two patients treated with mirabegron were found dead during follow-up. They were both considered high risk for sudden cardiac death, and their deaths were most probably due to a cardiac cause. Four patients, one treated with mirabegron and three given placebo, received appropriate ICD shocks for VT/VF ( Table 4 ). All four completed the study without further adverse events. In summary, fatal or life-threatening events occurred in three patients in each treatment group.
Additional details of adverse events are given in the Supplementery material online.
Discussion
The primary endpoint, an increase in LVEF, was not altered by treatment with the 3 AR agonist, mirabegron, in the entire study group. However, for patients treated with mirabegron, the exploratory analysis showed an increase in mean LVEF of patients with a CT LVEF <40% at baseline, while there was a small, non-significant decrease in LVEF after 6 months for patients with a baseline CT LVEF ≥40%. In agreement with these findings, exploratory analysis also showed that baseline LVEF predicted the degree of change in LVEF for the entire group of patients treated with mirabegron while it was not predictive at all for placebo-treated patients. These results are consistent with a likely dependence on LVEF of pathophysiological substrates targeted by treatment with a 3 AR agonist. The aetiology of heart failure was ischaemia in about half of the patients in both groups, similar to the fraction (53.1%) in the recent SOCRATES-REDUCED trial. 15 In both groups, two-thirds of the patients had an ICD or a CRT device implanted, and ∼55% had experienced cardiac arrest, sustained VT, and/or appropriate ICD shock therapy. These relatively high complication rates . for heart failure most probably reflect recruitment in a tertiary referral centre, but probably also that we recruited younger patients (mean age 59 years) compared with a mean age of 68 years in the SOCRATES-REDUCED trial. 15 The therapy included a beta-blocker in all cases (inclusion criteria). Different beta-blockers were administered, but in both groups the majority (>90%) were treated with carvedilol or metoprolol. Only one patient was treated with nebivolol. Mean beta-blocker doses were >75% of recommended target doses in both groups. An ACE/ARB was administered in 97% of the patients. Thus, most of the patients were well treated, stable and in NYHA class II, which is in agreement with the only slightly abnormal VO 2 max and NT-proBNP levels.
A modest increase in [Na + i ] enhances contractility in normal myocardium 10 and, conversely, a decrease in [Na For between-group differences, 95% confidence intervals (CIs) and P-values are for between-group comparisons for changes from baseline to follow-up. Numbers for between-group differences differ by 1 unit from that subtracted within-group changes for some data due to rounding-off of raw data.
reduces contractility.
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3 AR agonist-induced activation of the Na + -K + pump-mediated Na + i export 9 is therefore expected to have opposite effects in failing and non-failing heart ( Figure 3A) . Effects of a 3 AR agonist on cardiac performance in normal sheep vs. sheep with severe heart failure supported these predictions. 9 Raised levels of [Na
10 and oxidative stress 16, 17 targeted by treatment with a 3 AR agonist 18 have been demonstrated in the myocardium from patients with markedly reduced LVEF. While these levels are not known for patients in this study, it is reasonable to expect they are smaller for the proportion of patients with LVEF ≥40% than for patients with LVEF <40% and, if that is the case, a gradient of pathophysiological substrates responsive to treatment with mirabegron would make baseline LVEF predictive of the degree of change in LVEF, as we found. For the mechanism of action of 3 AR agonists it is noteworthy that patients with LVEF <40% on CT ( Table 3 ) had more dilated left ventricles (LVEDV and LVESV) as compared with the entire cohort ( Table 2 ). The significant increase in stroke volume in the mirabegron-treated patients compared with controls was related to a reduction in systolic and unaltered diastolic volumes. Similar changes were reported for carvedilol. dilated left ventricles, rather than induction of remodelling with reduced diastolic dimensions. It should be noted that the observed increases in LVEF and in stroke volume in the exploratory analysis were not related to reduced heart rates. This is opposite to findings in a study assessing the 6-month effect of carvedilol on LVEF in 29 patients with heart failure (LVEF 25 ± 9%), where roughly half of the identified increase in LVEF of 7% points was related to a carvedilol-induced reduction in heart rate.
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An increase in LVEF or stroke volume does not necessarily predict favourable hard clinical endpoints because inotropic agents have a poor long-term track record in heart failure. 20 However, it does not predict harm either. As noted LVEF also increases with beta-blocker treatment as reported for carvedilol in patients with severely reduced LVEF. 19 In addition, the mechanism for the increase is important. Most of the clinically used inotropic drugs raise cAMP levels through 1/ 2 AR stimulation or phosphodiesterase inhibition. 21 Within a paradigm of Na + iand NADP oxidase-dependent pathophysiology, this is expected to be harmful because cAMP activates NADPH oxidase in cardiac myocytes and causes oxidative Na + -K + pump inhibition. 22 In contrast, signalling of the 3 AR through a nitric oxide (NO)-, soluble guanylyl cyclase (sGC)-, and cGMP-dependent pathway Table 3 Changes from baseline to 6-month follow-up between groups in patients with baseline left ventricular ejection fraction by computed tomography <40%
Placebo (n = 17)
Mirabegron (n = 8) Between-group difference (95% CI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Changes over time in patients who completed follow-up (n = 61). Data are presented as mean ± SD. For between-group differences, 95% confidence intervals (CIs) and P-values are for between-group comparisons for changes from baseline to follow-up. Numbers for between-group differences differ by 1 unit from that subtracted within-group changes for some data due to rounding-off of raw data. In the placebo group, four had an implantable cardioverter defibrillator (ICD) implanted and in the mirabegron group three patients had an ICD implanted (P = 0.46). For CRT-D implants, the numbers were six and five (P = 0.20).
generally has antioxidant effects 18, 23 and stimulates the Na + -K + pump.
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Albeit indirect, potential long-term outcomes of 3 AR stimulation can be garnered from human trials. In patients with heart failure, central sympathetic inhibition with moxonidine reduced norepinephrine levels but surprisingly increased cardiac mortality. 24, 25 The autonomic nervous system was deemed 'unsympathetic' in heart failure. 26 We suggest that, whereas a decrease in 1/ 2 AR activity with reduced norepinephrine levels had some beneficial effects similar to usual 1/ 2 AR blockade, there was also loss of norepinephrine-induced reversal of oxidative Na + -K + pump inhibition mediated by the 3 AR 9 that has a high affinity for norepinephrine. 27 By inference, 3 AR stimulation might be useful long term in heart failure.
Administration of mirabegron in the dose recommended for treatment of urinary symptoms or in the six-fold higher target dose had no adverse effects. The expectation that use of a 3 AR agonist for non-cardiac indications might be particularly harmful in heart failure 7 was therefore not substantiated. This is important for treatment with mirabegron for symptomatic overactive bladder that is a common condition with an incidence that is further increased by diuretics in the treatment of heart failure. 28 It is reassuring that in heart failure patients mirabegron treatment did . We propose the pathophysiological substrate that remains with conventional treatment is targeted by 3 AR. 18 As discussed previously, rather than the partial prevention of Na + -K + pump inhibition by neurohormonal blockade, 3 AR agonists actively stimulate the pump. 29 Amongst the complex network of redox-dependent abnormalities in heart failure, 30 the roles we propose for receptor-coupled regulation of NADPH oxidase and the Na + -K + pump are summarized in Figure 3B .
A promising different way to activate sGC downstream from the 3 AR ( Figure 3B ) has been investigated in heart failure with reduced LVEF. Treatment with the sGC activator cinaciguat improved haemodynamic variables in acute decompensated heart failure but there was a prohibitively high incidence of hypotension. 31 In a dose-finding study of vericiguat in patients with worsening chronic heart failure, the primary endpoint was not achieved, but in an exploratory analysis vericiguat significantly improved LVEF compared with placebo by 12 weeks (3.7% vs. 1.2%). 15 At the highest dose, it reduced NT-proBNP levels but also increased the incidence of hypotension.
Activators of sGC have effects on NADPH oxidase and the cardiac myocyte Na + -K + pump 18, 32 in vitro that are similar to effects of 3 AR agonist treatment of rabbits with heart failure. In contrast to sGC activators, the 3 AR agonists had no effect on blood pressure in this study, which favours 3 AR agonists
Limitations
The design of this first-in-man study was mainly based on laboratory and clinical findings in normal and heart failure models using small and large animals, combined with clinical trial data on mirabegron given to patients at different doses for overactive bladder. There was no guidance in the literature for choice of dose, duration of treatment, primary endpoint, or which patients would benefit the most. The inclusion criterion were set at a preliminary LVEF <40% by echocardiography, but might as well have been <45% as used in the recent SOCRATES-REDUCED trial. 15 The reported echocardiography LVEF was determined blinded at the end of the study, and in five cases LVEF was in the interval from 40 to 46%. Considering the general scatter of interobserver LVEF determined by echocardiography with an SD of 7.6 LVEF units and of intraobserver determinations with an SD of 8.3 LVEF units, 33 is not surprising. The final LVEF readings above 40% are not jeopardizing the study results as all the patients had heart failure with reduced systolic function, and a higher LVEF at inclusion might as well have been chosen for the design. The patients were all stable and on maximum tolerated medical heart failure therapy and had CRT-D implants according to guidelines. This was reflected by only mildly abnormal 6-min walking distance, VO 2 max, and NT-proBNP levels. In this setting, it may be a challenge for new drugs to induce an improvement. Nevertheless, the results indicate that mirabegron may only improve systolic function in patients with more severe heart failure and perhaps specifically in patients with more pronounced LV dilatation, whereas no benefit might be seen in those with less severe heart failure. Taken together, the results obtained in this first-in-man study allows us to propose that the next study of a 3 AR agonist in heart failure should include patients with more severe heart failure, NYHA class III-IV, dilated left ventricles, and significantly raised levels of NT-pro-BNP.
Conclusion
Treatment with mirabegron was well tolerated and appeared safe. It had no effect on the primary endpoint, but mechanistically plausible results of the exploratory analysis indicate that 3 AR agonists potentially are beneficial in treatment of heart failure with reduced LVEF. Additional studies are justified to determine the efficacy and In the non-failing heart, a modest increase in the intracellular Na + concentration ([Na i ]) and, via Na-Ca exchange, [Ca i ] increases energy-dependent Ca uptake into the sarcoplasmic reticulum (SR). This increases the amount of Ca-induced SR Ca release via the ryanodine receptor (RyR) on activation of membrane Ca channels in systole, increases cytosolic Ca transient, and increases contractility. Conversely, with reversal of the process on stimulation of Na + -K + pump-mediated Na i export, contractility is reduced. In the failing heart, an increase in already high [Na i ] increases cytosolic [Ca i ] that causes diastolic SR Ca leak and reduces systolic Ca transients and contractility. In addition, raised [Na i ] decreases synthesis of mitochondrial (Mit) ATP and increases synthesis of superoxide (O 2 ⋅ − ). Na + -K + pump-mediated Na i export reverses these process and increases contractility. (B) Activation of angiotensin (Ang II) type I receptors (AT1) causes protein kinase C (PKC)-dependent phosphorylation of the p47 phox subunit of NADPH oxidase that triggers its translocation to membranous subunits and activation of O 2 ⋅ − synthesis. Activation of 1/ 2 adrenoceptors induces synthesis of cAMP, and activation of cAMP-dependent protein kinase (PKA) activates NADPH oxidase via a downstream pathway shared with the AT1 receptor. Activation of the mineralocorticoid receptor (MR) up-regulates NADPH oxidase. The 3 adrenoceptor ( 3) activates nitric oxide (NO) synthase (NOS), and soluble guanylyl cyclase (sGC) activated by NO synthesizes cGMP that activates protein kinase G (PKG). Activation of protein phosphatases 2A (PP2A) then dephosphorylates p47 phox and inactivation of NADPH oxidase reduces oxidative stress and Na + -K + pump inhibition. optimal dose of 3 AR agonists in patients with severely reduced systolic function.
Supplementary Information
Additional Supporting Information may be found in the online version of this article: Online-only Data Supplement
